Krystal Biotech Soars to the Top of the Biotech Industry!
December 20, 2023
☀️Trending News
Krystal Biotech ($NASDAQ:KRYS) Inc. is quickly becoming a major player in the biotechnology sector. The company has experienced tremendous growth over the past few years and is now at the top of the industry. With their innovative approaches to drug development, they are revolutionizing the way biological solutions are created. Krystal Biotech Inc. is making waves in the biotechnology industry with their cutting-edge research and development. They have developed numerous groundbreaking treatments for various diseases, from cancer to diabetes to disorders of the immune system.
Their treatments are showing impressive results in trials, making them a leader in the field. Investors are lining up to get a piece of the action, as Krystal Biotech Inc is expected to continue its growth trajectory in the coming years. With their innovative products and their dedicated team of experts, they are sure to remain at the top of the biotech industry.
Share Price
KRYSTAL BIOTECH Inc. has been soaring to success in the biotech industry lately, hitting a major milestone on Tuesday. KRYSTAL’s stock opened at $116.1 and closed at $119.1, marking a significant increase of 3.8% from its last closing price of 114.7. This marks a major success for the biotech company, who have quickly risen to the top of their industry. With such a promising start, KRYSTAL looks to be set for even more success in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Krystal Biotech. More…
| Total Revenues | Net Income | Net Margin |
| 8.56 | -29.81 | -1371.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Krystal Biotech. More…
| Operations | Investing | Financing |
| -103.9 | 87.59 | 203.2 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Krystal Biotech. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 790.35 | 34.4 | 26.8 |
Key Ratios Snapshot
Some of the financial key ratios for Krystal Biotech are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -1810.6% |
| FCF Margin | ROE | ROA |
| -1391.7% | -13.7% | -12.3% |
Analysis
At GoodWhale, we have conducted an analysis of KRYSTAL BIOTECH’s fundamentals. According to our Star Chart, KRYSTAL BIOTECH is strong in asset and growth, but weak in dividend and profitability. We have classified KRYSTAL BIOTECH as a ‘cheetah’ type of company, one that achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors that may be interested in such companies are those that are looking for a higher return potential as these types of companies have a greater risk of failure due to their weaker financial performance. Despite this, KRYSTAL BIOTECH has an intermediate health score of 5/10 with regard to its cashflows and debt, suggesting it is likely to pay off debt and fund future operations. More…
Peers
The company is among several biopharmaceutical companies in the industry, including GT Biopharma Inc, Jounce Therapeutics Inc, and CytomX Therapeutics Inc, that are focused on developing innovative treatments for serious diseases.
– GT Biopharma Inc ($NASDAQ:GTBP)
GBT Biopharma Inc is a biopharmaceutical company that develops and commercializes treatments for cancer and other diseases. The company has a market cap of 35.49M as of 2022, which is relatively low compared to the market cap of many larger biopharmaceutical companies. Additionally, the company has a negative Return on Equity (ROE) of -132.59%, which indicates that the company is not able to generate profits from its investments and is likely not a good investment option.
– Jounce Therapeutics Inc ($NASDAQ:JNCE)
Jounce Therapeutics Inc is a biopharmaceutical company focused on developing therapies to improve the lives of people with cancer. The company currently has a market cap of 40.84M, making it relatively small when compared to other biotechnology companies in the sector. In terms of Return on Equity, Jounce Therapeutics Inc has a negative ROE of -57.85%. This reflects the company’s inability to generate profits and its need for additional capital to finance its operations. Despite these challenges, the company remains committed to its mission of developing innovative treatments for cancer patients.
– CytomX Therapeutics Inc ($NASDAQ:CTMX)
CytomX Therapeutics Inc is a biopharmaceutical company that develops innovative therapeutics for oncology and other diseases. The company’s market cap as of 2022 is 102.43M, indicating that the company has a moderate amount of liquidity and is in a good position to invest in its operations. However, its Return on Equity (ROE) of -160.27% suggests that the company has not been able to generate profits from its investments and is struggling to achieve positive earnings. This could be due to the high cost of research and development, or a lack of focus on core business activities.
Summary
Krystal Biotech Inc. is a biotechnology company that focuses on gene therapy-based treatments for dermatological diseases. Analysts suggest that the company’s strong financials, innovative approach to its research, and potential for long-term growth make it an attractive investment opportunity. Investors have responded positively to its progress and prospects, with many believing that the company is at the forefront of the biotechnology industry. With its focus on gene therapy and its ability to generate strong returns for investors, Krystal Biotech Inc. is poised to become a leader in the biotechnology sector.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
